Abstract:Bulleyaconitine A, a diterpenoid alkaloid isolated from Aconitum bulleyanum plants, has been used for the treatment of chronic pain in China since 1985. Clinical studies show that the oral administration of bulleyaconitine A is effective for treating different kinds of chronic pain, including back pain, joint pain, and neuropathic pain with minimal side effect in human patients. The experimental studies have revealed that bulleyaconitine A at therapeutic doses potently inhibits the peripheral sensitization and central sensitization that underlie chronic pain and has no effect on acute pain. Bulleyaconitine A preferably blocks tetrodotoxin-sensitive voltage-gated sodium channels in dorsal root ganglion neurons by inhibition of protein kinase C, and the effect is around 600 times more potent in neuropathic animals than in naïve ones. Bulleyaconitine A at 5 nM inhibits the hypersensitivity of dorsal root ganglion neurons in neuropathic rats but has no effect on excitability of dorsal root ganglion neurons in sham group. Bulleyaconitine A inhibits long-term potentiation at C-fiber synapses in spinal dorsal horn, a synaptic model of pathological pain, preferably in neuropathic pain rats over naïve rats. The following mechanisms may underlie the selective effect of bulleyaconitine A on chronic pain. (1) In neuropathic conditions, protein kinase C and voltage-gated sodium channels in dorsal root ganglion neurons are upregulated, which enhances bulleyaconitine A's effect. (2) Bulleyaconitine A use-dependently blocks voltage-gated sodium channels and therefore inhibits the ectopic discharges that are important for neuropathic pain. (3) Bulleyaconitine A is shown to inhibit neuropathic pain by the modulation of spinal microglia, which are involved in the chronic pain but not in acute (nociceptive) pain. Moreover, bulleyaconitine A facilitates the anesthetic effect of morphine and inhibits morphine tolerance in rats. Together, bulleyaconitine A is able to inhibit chronic pain by targeting at multiple molecules. Further clinical and experimental studies are needed for evaluating the efficacy of bulleyaconitine A in different forms of chronic pain in patients and for exploring the underlying mechanisms.

Bulleyaconitine A Inhibits Visceral Nociception and Spinal Synaptic Plasticity through Stimulation of Microglial Release of Dynorphin A

Aconitum-Derived Bulleyaconitine A Exhibits Antihypersensitivity Through Direct Stimulating Dynorphin A Expression in Spinal Microglia

Aconitum-derived bulleyaconitine A exhibits anti-hypersensitivity through direct stimulating dynorphin A expression in spinal microglia.

Bulleyaconitine A Exerts Antianxiety and Antivisceral Hypersensitivity Effects.

Bulleyaconitine A Inhibits Morphine-Induced Withdrawal Symptoms, Conditioned Place Preference, and Locomotor Sensitization Via Microglial Dynorphin A Expression

Bulleyaconitine A inhibits morphine physical and psychological dependence via dynorphin A expression

Molecular Signaling Underlying Bulleyaconitine A (Baa)-Induced Microglial Expression of Prodynorphin

Oral application of bulleyaconitine A attenuates morphine tolerance in neuropathic rats by inhibiting long-term potentiation at C-fiber synapses and protein kinase C gamma in spinal dorsal horn

Bulleyaconitine A attenuates hyperexcitability of dorsal root ganglion neurons induced by spared nerve injury: The role of preferably blocking Nav1.7 and Nav1.3 channels

Concurrent Bullatine A Enhances Morphine Antinociception and Inhibits Morphine Antinociceptive Tolerance by Indirect Activation of Spinal Κ-Opioid Receptors.

Mechanisms for Therapeutic Effect of Bulleyaconitine A on Chronic Pain

Mechanisms for therapeutic effect of bulleyaconitine A on chronic pain.

Bullatine A Stimulates Spinal Microglial Dynorphin A Expression to Produce Anti-Hypersensitivity in a Variety of Rat Pain Models.

Bulleyaconitine A depresses neuropathic pain and potentiation at C-fiber synapses in spinal dorsal horn induced by paclitaxel in rats

Bulleyaconitine A preferably reduces tetrodotoxin-sensitive sodium current in uninjured dorsal root ganglion neurons of neuropathic rats probably via inhibition of protein kinase C.

P2X receptor-mediated visceral hyperalgesia in a rat model of chronic visceral hypersensitivity.

Cyclic Analogues of Α‐conotoxin Vc1.1 Inhibit Colonic Nociceptors and Provide Analgesia in a Mouse Model of Chronic Abdominal Pain

The Anti-Nociceptive Effect of BmK AS, a Scorpion Active Polypeptide, and the Possible Mechanism on Specifically Modulating Voltage-Gated Na+ Currents in Primary Afferent Neurons

Sex-differential modulation of visceral pain by brain derived neurotrophic factor (BDNF) in rats.

Effects of Endokinin A/B and Endokinin C/D on the modulation of pain in mice.

Ester Hydrolysis Differentially Reduces Aconitine-Induced Anti-hypersensitivity and Acute Neurotoxicity: Involvement of Spinal Microglial Dynorphin Expression and Implications for Aconitum Processing